Clinical Trial Update: A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial update on the combination of rituximab and varlilumab immunotherapy in patients with B-cell lymphoma, now completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Varlilumab (varlilumab)

Snippet

Sponsor: University Hospital Southampton NHS Foundation Trust | Conditions: B Cell Lymphoma | Phase 1, Phase 2 | Status: COMPLETED